Clinical Dosimetry Models and Pathway to Integration in Routine Nuclear Medicine Practice.

An increasing interest in radiopharmaceutical therapy (RPT), especially in reference to the theranostic framework incorporating both diagnostic and therapeutic components have been reported. Typically, this "theranostic approach" consists of a "matching pair" of radiopharmaceuticals, comprising a diagnostic partner labelled with positron or gamma-emitting radionuclides and a therapeutic partner labelled with beta or alpha-emitting radionuclides. Due to variability in the biodistribution, uptake, and retention, the therapeutic effectiveness of established and newer radiopharmaceutical therapies may show interpatient and intrapatient variability. As RPT requires the systemic administration of radiopharmaceuticals to patients, their normal organ biodistribution, as well as uptake in tumor tissues, can be mapped using molecular imaging (SPECT and PET) techniques. This allows for the quantification of the fraction of the administered radioactivity (MBq) that reaches the tumor, as well as the normal organs. The administered radioactivity can be modified based upon a patient's body habitus and laboratory parameters to achieve the optimal and desired tumor effect and normal tissue sparing, thereby permitting delivery of an individualized theranostics. This review discusses the RPT and dosimetry practices that are in clinical use, along with other cutting-edge radiopharmaceutical therapies that have shown promising therapeutic efficacies in advanced-stage human malignancies.

• Publication year

  2026

• Venue

  Clinical Nuclear Medicine

• Publication date

  2026-02-05

• Fields of study

  Medicine, Physics, Engineering

• Identifiers
  DOI 10.1097/RLU.0000000000006180PMID 41632582
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials

  2024cited by this paper
• 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.

  2024cited by this paper
• A practical method for assessing quantitative scanner accuracy with long-lived radionuclides: The ARTnet insert

  2024cited by this paper
• A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?

  2024cited by this paper
• An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 3: Contribution from Calculating Absorbed Dose from Time-Integrated Activity

  2024cited by this paper
• Actinium-225 in Targeted Alpha Therapy

  2024cited by this paper
• How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design.

  2024cited by this paper
• Linear Boltzmann equation solver for voxel-level dosimetry in radiopharmaceutical therapy: Comparison with Monte Carlo and kernel convolution

  2024cited by this paper
• Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation

  2023cited by this paper
• 68Ga-Pentixafor PET/CT for in-vivo mapping of CXCR4 receptors as potential radiotheranostic targets in soft tissue and bone sarcoma: preliminary results

  2023cited by this paper
• Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence

  2023cited by this paper
• A novel model-based equation for size dependent mean recovery coefficients for spheres and other shapes.

  2023cited by this paper
• India's Growing Nuclear Medicine Infrastructure and Emergence of Radiotheranostics in Cancer Care: Associated Challenges and the Opportunities to Collaborate

  2023cited by this paper
• Quality assurance in clinical dosimetry.

  2023cited by this paper
• Single-Time-Point Imaging for Dosimetry After [177Lu]Lu-DOTATATE: Accuracy of Existing Methods and Novel Data-Driven Models for Reducing Sensitivity to Time-Point Selection

  2023cited by this paper
• Answering the Call for Radiation Oncologists to Direct Radiopharmaceutical Therapy: Forget the Professional Fee and Get the Hospital to Pay for Support Staff, Infrastructure, and Supplies.

  2023cited by this paper
• MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry

  2023cited by this paper
• Activity recovery for differently shaped objects in quantitative SPECT

  2023cited by this paper
• Theranostic Radiopharmaceuticals: A Universal Challenging Educational Paradigm in Nuclear Medicine

  2023cited by this paper
• An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 2: Overall Variabilities in Absorbed Dose

  2023cited by this paper
• OLINDA/EXM 2—The Next-generation Personal Computer Software for Internal Dose Assessment in Nuclear Medicine

  2023cited by this paper
• A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients

  2023cited by this paper
• Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy

  2023cited by this paper
• A Pipeline for Automated Voxel Dosimetry: Application in Patients with Multi-SPECT/CT Imaging After 177Lu-Peptide Receptor Radionuclide Therapy

  2022cited by this paper
• Dosimetry in targeted alpha therapy. A systematic review: current findings and what is needed

  2022cited by this paper
• Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study.

  2022cited by this paper
• EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

  2022cited by this paper
• [^68Ga]Ga-Pentixafor PET/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: correlation with quantitative receptors’ density by immunochemistry techniques

  2022cited by this paper
• Dosimetry in Radiopharmaceutical Therapy

  2022cited by this paper
• Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer

  2022cited by this paper
• Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA

  2022cited by this paper
• Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review

  2022cited by this paper
• DblurDoseNet: A deep residual learning network for voxel radionuclide dosimetry compensating for single-photon emission computerized tomography imaging resolution

  2022cited by this paper
• Fully Automated, Semantic Segmentation of Whole-Body 18F-FDG PET/CT Images Based on Data-Centric Artificial Intelligence

  2022cited by this paper
• TotalSegmentator: Robust Segmentation of 104 Anatomic Structures in CT Images.

  2022cited by this paper
• Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy

  2022cited by this paper
• Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy

  2022cited by this paper
• Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT

  2022cited by this paper
• Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs

  2022cited by this paper
• Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective

  2022cited by this paper
• Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients

  2022cited by this paper
• Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns.

  2021cited by this paper
• [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

  2021cited by this paper
• High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma

  2021cited by this paper
• DblurDoseNet: A deep residual learning network for voxel radionuclide dosimetry compensating for SPECT imaging resolution.

  2021cited by this paper
• Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients

  2021cited by this paper
• Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels

  2021cited by this paper
• Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

  2021cited by this paper
• Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results

  2021cited by this paper
• Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

  2021cited by this paper
• A Projection-Domain Low-Count Quantitative SPECT Method for α-Particle-Emitting Radiopharmaceutical Therapy

  2021cited by this paper
• Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177Lu-DOTATATE

  2021cited by this paper
• Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer

  2021cited by this paper
• Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients

  2021cited by this paper
• A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors

  2021cited by this paper
• Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes

  2021cited by this paper
• Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry

  2021cited by this paper
• Iodine-131 and Iodine-131-Meta-iodobenzylguanidine Dosimetry in Cancer Therapy.

  2021cited by this paper
• An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 1: Design and Early Results of the SNMMI Dosimetry Challenge.

  2021cited by this paper
• Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities.

  2021cited by this paper
• Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.

  2021cited by this paper
• 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma

  2020cited by this paper
• An international multi-center investigation on the accuracy of radionuclide calibrators in nuclear medicine theragnostics

  2020cited by this paper
• Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points

  2020cited by this paper
• Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity

  2020cited by this paper
• 123I Scan With Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry Before 131I Treatment of Metastatic Thyroid Cancer.

  2020cited by this paper
• nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation

  2020cited by this paper
• 225Ac-PSMA-617 for Therapy of Prostate Cancer.

  2020cited by this paper
• Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 Update.

  2020cited by this paper
• Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment

  2020cited by this paper
• Whole-body voxel-based internal dosimetry using deep learning

  2020cited by this paper
• Author Correction: Radiopharmaceutical therapy in cancer: clinical advances and challenges

  2020cited by this paper
• Artificial Intelligence and Machine Learning in Nuclear Medicine: Future Perspectives.

  2020cited by this paper
• Modeling and Predicting Tumor Response in Radioligand Therapy

  2019cited by this paper
• A deep learning approach to radiation dose estimation

  2019cited by this paper
• Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE

  2019cited by this paper
• Deep-dose: a voxel dose estimation method using deep convolutional neural network for personalized internal dosimetry

  2019cited by this paper
• NCINM: a computational phantom-based dosimetry tool for patients undergoing nuclear medicine procedures

  2019cited by this paper
• Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for 131 I-MIBG therapy of neuroblastoma using 124 I-MIBG PET/CT.

  2019cited by this paper
• Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors

  2019cited by this paper
• Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review

  2018cited by this paper
• Technical Note: Single time point dose estimate for exponential clearance.

  2018cited by this paper
• Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days

  2018cited by this paper
• Effect of image registration on 3D absorbed dose calculations in 177Lu-DOTATOC peptide receptor radionuclide therapy.

  2018cited by this paper
• Determination of gamma camera calibration factors for quantitation of therapeutic radioisotopes

  2018cited by this paper
• Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma

  2018cited by this paper
• Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma

  2018cited by this paper
• Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?

  2017cited by this paper
• Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors

  2017cited by this paper
• Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model.

  2017cited by this paper
• Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

  2017cited by this paper
• Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force

  2017cited by this paper
• IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms

  2017cited by this paper
• First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease

  2016cited by this paper
• Dose–Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT

  2016cited by this paper
• Treatment of hyperthyroidism with radioiodine targeted activity: A comparison between two dosimetric methods.

  2016cited by this paper
• Optimized Peptide Amount and Activity for 90Y-Labeled DOTATATE Therapy

  2016cited by this paper
• Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides

  2016cited by this paper
• Physiologically Based Pharmacokinetic (PBPK) Model for Biodistribution of Radiolabeled Peptides in Patients with Neuroendocrine Tumours

  2016cited by this paper
• In vivo quantification of 177Lu with planar whole-body and SPECT/CT gamma camera imaging

  2015cited by this paper

• No citing papers are available for this paper.